Want to see JP:4594 full AI Analyst Report?
4594 Stock Chart & Stats
¥48.00
¥1.00(2.27%)
At close: 4:00 PM EST
¥48.00
¥1.00(2.27%)
Day’s Range― - ―
52-Week Range¥43.00 - ¥96.00
Previous CloseN/A
Volume188.00K
Average Volume (3M)1.50M
Market Cap
¥6.81B
Enterprise Value¥4.81K
Total Cash (Recent Filing)¥2.16B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.56
Shares Outstanding138,891,300
10 Day Avg. Volume1,219,240
30 Day Avg. Volume1,498,233
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.25
Price to Sales (P/S)91636.06
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low leverage reduces refinancing pressure and interest-related constraints, giving BrightPath greater flexibility while it funds research and development. This balance-sheet characteristic provides resilience against financing stress over the next several quarters, even though it does not offset operating losses.
Balance-sheet Asset BufferA sizable asset and equity base relative to the company’s scale offers some financial cushion as BrightPath continues developing its biotechnology programs. That buffer can support business continuity and strategic investment, although its durability depends on whether ongoing losses continue to reduce equity.
Losses Narrowed From Prior LevelsNarrower losses than in 2021 indicate some improvement in the company’s cost or operating profile over time, despite continuing unprofitability. If maintained, this could slow equity erosion and reduce the funding burden, creating a more sustainable base for future biotechnology development.
Bears Say
Severe Revenue VolatilityThe sharp revenue collapse after a one-year spike indicates that BrightPath’s current revenue base is unstable and may depend heavily on uneven milestone or other income. This limits visibility into commercial traction and makes it difficult to support recurring operating costs through internally generated revenue.
Persistent Deep LossesPersistent losses of this magnitude relative to the company’s small revenue base show that research and operating costs remain far above current earnings capacity. Continued unprofitability can erode equity, increase reliance on external funding, and delay the point at which the business can scale without financing support.
Sustained Cash BurnConsistently negative operating and free cash flow demonstrates that BrightPath is not currently self-funding its operations. Because free cash flow has not shown a durable improvement trend, ongoing development and corporate activities may require additional financing, increasing pressure on long-term financial flexibility.
BrightPath Biotherapeutics Co.Ltd. News
4594 FAQ
What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?
BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥43.00 and its highest was ¥96.00 in the past 12 months.
What is BrightPath Biotherapeutics Co.Ltd.’s market cap?
BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥6.81B.
When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?
BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 34 days.
How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?
BrightPath Biotherapeutics Co.Ltd. released its earnings results on Aug 14, 2026. The company reported -¥3.82 earnings per share for the quarter.
Is BrightPath Biotherapeutics Co.Ltd. overvalued?
According to Wall Street analysts BrightPath Biotherapeutics Co.Ltd.’s price is currently Overvalued.
Does BrightPath Biotherapeutics Co.Ltd. pay dividends?
BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.
What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?
BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?
BrightPath Biotherapeutics Co.Ltd. has 138,891,300 shares outstanding.
What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?
BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥3.82 in its last earnings report. Following the earnings report the stock price went up 1.961%.
Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?
Currently, no hedge funds are holding shares in JP:4594
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrightPath Biotherapeutics Co.Ltd.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
CellSource Co., Ltd.
―
StemCell Institute
―
CellSeed Inc.
―